Berberine is an isoquinoline alkaloid found in multiple traditional Chinese and Western medicinal plants, including Coptis chinensis (Huang Lian), Berberis vulgaris (barberry), and Mahonia aquifolium (Oregon grape). Extensive clinical evidence from multiple RCTs and meta-analyses demonstrates significant blood glucose reduction -- comparable to metformin in some head-to-head trials -- alongside clinically meaningful lipid-lowering effects. Its primary mechanism involves AMPK activation and mitochondrial complex I inhibition, with additional effects on gut microbiome modulation (increased Akkermansia and short-chain fatty acid production) and PCSK9 downregulation for cholesterol lowering. Berberine falls outside the European phytotherapy regulatory framework as an isolated alkaloid, though barberry root has some European traditional use history.

Bilberry fruit and its anthocyanin-rich extracts have a dual identity in European phytotherapy. The dried fruit is Commission E-approved for acute nonspecific diarrhea (due to tannin content) and mild oropharyngeal inflammation. The fresh fruit extract, standardized to 25% anthocyanins (as Myrtocyan/Mirtoselect), is used for peripheral vascular insufficiency and capillary fragility, with ESCOP and EMA recognition. Clinical evidence for vascular indications is moderate, with several controlled trials showing improvements in capillary resistance and microcirculation. The popular claim of improved night vision originated from WWII-era anecdotal reports and has not been consistently supported by rigorous trials.

Butcher's Broom (Ruscus aculeatus) is Commission E-approved for supportive therapy of CVI and hemorrhoids. Its active compounds -- the steroidal saponins ruscogenin and neoruscogenin -- have vasoconstrictive and anti-inflammatory effects on venous tissue. The evidence base is smaller than for horse chestnut, with most clinical trials using combination products (ruscus + hesperidin methylchalcone + ascorbic acid). One key multi-center RCT demonstrated significant leg volume reduction. It is a second-line venoactive drug in European phytotherapy.

Danshen (Salvia miltiorrhiza) is one of the most important cardiovascular herbs in Traditional Chinese Medicine, used for millennia to "activate blood and resolve stasis." The root contains lipophilic tanshinones (tanshinone IIA, cryptotanshinone) and hydrophilic phenolic acids (salvianolic acid B, danshensu) with demonstrated antiplatelet, vasodilatory, antioxidant, and cardioprotective properties. Compound Danshen Dripping Pills (CDDP/T89) is one of the most widely used cardiovascular herbal preparations in China and has undergone FDA Phase III trials for chronic stable angina. Multiple Cochrane reviews cover danshen for acute ischemic stroke and angina, though they consistently note that included Chinese trials have significant methodological limitations. No European regulatory monographs exist. The evidence is moderate -- pharmacologically compelling with extensive Chinese clinical data, but limited by trial quality and the predominance of combination formulas.

Garlic is Commission E-approved for supportive treatment of elevated blood lipids and prevention of age-dependent vascular changes. Meta-analyses of older trials showed approximately 12% reductions in total cholesterol with garlic powder (600-900 mg/day), but more recent high-quality trials have shown more modest effects. The most compelling cardiovascular evidence comes from a 4-year study showing significant inhibition of atherosclerotic plaque progression. Garlic has an excellent safety profile but interacts with anticoagulants and CYP450 substrates.

Gotu kola (Centella asiatica) is notable for bridging Western phytotherapy and Ayurvedic traditions. In European medicine, its primary evidence-based application is chronic venous insufficiency (CVI), where the standardized Total Triterpenic Fraction of Centella asiatica (TTFCA, containing asiaticoside, madecassoside, asiatic acid, madecassic acid) has demonstrated significant improvements in venous tone, capillary permeability, and microcirculation in multiple controlled trials. It also has well-documented wound-healing and scar-reduction properties. The EMA/HMPC has granted traditional use status for heavy legs related to venous disturbances and minor wound healing. Commission E and ESCOP have not issued monographs, reflecting a gap between the existing clinical evidence and formal European regulatory recognition.

Grape seed extract (GSE) is a concentrated source of oligomeric proanthocyanidins (OPCs), typically standardized to 95% or greater OPC content. Meta-analyses of RCTs demonstrate modest but consistent blood pressure reductions, particularly for diastolic blood pressure (-2.2 mmHg) and heart rate (-1.25 bpm), with benefits most pronounced in younger, obese, or metabolically compromised individuals. The primary mechanism involves enhanced endothelial nitric oxide synthase (eNOS) expression and increased nitric oxide production, leading to vasodilation and improved endothelial function. Additional evidence supports use in chronic venous insufficiency and as a systemic antioxidant. No European regulatory body (Commission E, ESCOP, EMA) has published a monograph specifically for grape seed, though the EMA has a monograph for Vitis vinifera leaf (a different plant part used as Red Vine Leaf). GSE is distinct from Red Vine Leaf extract both botanically (seed vs leaf) and in its evidence profile. The clinical evidence is moderate in quality -- multiple independent research groups have contributed, but studies remain generally small and short-term.

Green tea (Camellia sinensis) and its principal catechin EGCG have moderate-to-strong evidence for modest improvements in cardiovascular risk factors, with meta-analyses of 31+ RCTs demonstrating reductions in LDL cholesterol (~4.5 mg/dL), total cholesterol (~4.7 mg/dL), and systolic blood pressure (~2 mmHg). Evidence for weight management is consistent but effect sizes are small (approximately 1 kg over 12 weeks). Cancer prevention data from pooled observational studies suggest a 9% risk reduction (RR 0.91), though individual RCTs have shown mixed results. The EFSA identified 800 mg/day of EGCG from supplements as a threshold above which hepatotoxicity risk increases, distinguishing the safety profile of concentrated extracts from traditional green tea infusions. The EMA/HMPC grants traditional use status for symptoms of fatigue and asthenia.

Hawthorn extract WS 1442 is the most rigorously studied herbal cardiac medicine. It has Commission E approval for NYHA II heart failure, ESCOP and EMA/HMPC monograph support, and was tested in a 2,681-patient mortality trial (SPICE). While the SPICE trial did not meet its primary endpoint, it demonstrated excellent safety alongside optimal heart failure medication and showed a significant reduction in sudden cardiac death in the NYHA III subgroup. The mechanism involves positive inotropy without increased myocardial oxygen demand -- a unique pharmacological profile among cardiac agents.

Hibiscus (roselle) calyx tea is one of the better-studied herbal interventions for mild-to-moderate hypertension. Multiple RCTs and meta-analyses show significant reductions in systolic blood pressure (approximately 7 mmHg) and diastolic blood pressure (approximately 4 mmHg) compared to placebo. The anthocyanins delphinidin-3-sambubioside and cyanidin-3-sambubioside appear to act via ACE inhibition and endothelial nitric oxide synthase upregulation. Despite this growing evidence base, hibiscus has no Commission E, ESCOP, or EMA monograph. It is widely consumed as a traditional beverage (karkade) across Africa, the Middle East, and Latin America. The safety profile is favorable, with minor GI disturbances as the main side effect, though potential interactions with antihypertensive medications (particularly ACE inhibitors and diuretics) warrant caution.

Horse chestnut seed extract (HCSE) standardized to aescin (escin) has the strongest evidence base of any herbal treatment for chronic venous insufficiency (CVI). A Cochrane review of 17 RCTs found consistent significant reductions in leg pain, edema, and leg volume. In some trials, HCSE was comparable to compression stockings. It is approved by Commission E, has ESCOP and EMA/HMPC monographs, and is widely prescribed in Germany. In the US, CVI is an undertreated condition and HCSE is virtually unknown to mainstream physicians.

Nigella sativa (black seed) is a traditional medicinal plant whose principal bioactive constituent, thymoquinone, has demonstrated cardiovascular-relevant pharmacological activity including antioxidant, anti-inflammatory, calcium channel blocking, and ACE-inhibitory effects. A 2025 GRADE-assessed meta-analysis of 82 RCTs (n=5,026) found statistically significant reductions in systolic blood pressure (~3 mmHg), diastolic blood pressure (~2.7 mmHg), total cholesterol, LDL-cholesterol, and triglycerides with Nigella sativa supplementation, though effect sizes are modest and clinical significance is uncertain. Evidence quality is limited by heterogeneous methodology, small sample sizes, and variable extract standardization. No European regulatory body (Commission E, ESCOP, EMA/HMPC) has issued a monograph for Nigella sativa. The seed is FDA GRAS for food use and generally well tolerated at doses up to 3 g/day, but has potential interactions with warfarin, antihypertensives, and hypoglycemic agents via CYP2C9 and CYP3A4 inhibition.

Olive leaf extract (Olea europaea L., folium) is an emerging antihypertensive herbal medicine with roots in Mediterranean traditional medicine. The landmark Susalit 2011 trial (n=232) demonstrated that olive leaf extract (500 mg twice daily, equivalent to ~200 mg oleuropein/day) was non-inferior to captopril 12.5-25 mg twice daily for stage-1 hypertension over 8 weeks. The mechanism involves ACE inhibition via oleuropein and oleacein. While the EMA/HMPC has published a monograph on olive leaf, it is for "traditional use" for mild water retention -- not for hypertension. This represents a case where clinical trial data has outpaced regulatory recognition.

Pycnogenol is a standardized extract of French maritime pine bark (Pinus pinaster) containing 65-75% procyanidins (oligomeric proanthocyanidins, OPCs). It is one of the most extensively studied botanical extracts, with over 100 clinical trials and 39+ RCTs across diverse indications. The strongest evidence supports its use in chronic venous insufficiency (CVI), where multiple RCTs have demonstrated significant reductions in leg edema, heaviness, and pain -- in one study, Pycnogenol alone was more effective than compression stockings. A 2025 meta-analysis of 27 RCTs confirmed significant blood pressure reductions (SBP -2.26 mmHg, DBP -2.62 mmHg). Additional evidence exists for blood glucose management, skin health, cognitive function, and joint health. Despite this extensive clinical portfolio, no European regulatory body (Commission E, ESCOP, EMA) has published a monograph for pine bark. This reflects the fact that Pycnogenol is a modern proprietary extract without the centuries of traditional European use that typically underpins regulatory monographs. The evidence base, while large, is concentrated among a small group of investigators with industry ties.

Pomegranate is a fruit with a long history in Ayurvedic and traditional medicine, now subject to considerable modern research interest for cardiovascular and prostate health. The fruit and its extracts are exceptionally rich in punicalagins, ellagitannins, and ellagic acid, which are potent antioxidants. Multiple meta-analyses of RCTs suggest a modest blood pressure-lowering effect, though individual trial results are inconsistent. Early research on PSA doubling time in prostate cancer patients generated significant excitement, but larger placebo-controlled trials failed to confirm the effect. No European regulatory body (Commission E, ESCOP, or EMA) has issued a monograph for pomegranate. It remains a food/dietary supplement with promising but unconfirmed therapeutic potential.

Red vine leaf extract (AS 195, marketed as Antistax) is a flavonoid-rich phytomedicine used for mild-to-moderate chronic venous insufficiency (CVI). Standardized to quercetin-3-O-beta-glucuronide, it has demonstrated significant edema reduction and symptom improvement in multiple RCTs at doses of 360-720 mg/day. The EMA/HMPC has granted traditional use status. It represents a well-tolerated option for early-stage CVI that has been marketed in France for over 70 years and is now available across multiple European countries.